Table 6 Clinical and preclinical trials using stem cells as delivery vehicle for OAV
Cancer | Vehicle | Construct | Transgene/Feature | Administration | Phase | ClinicalTrials. gov ID | Ref. | Combination |
|---|---|---|---|---|---|---|---|---|
Liver cancer | MSC | MSC-rAdCD3scFv | anti-CD3scFv | Preclinical | [219] | LentiR.E1A, 5-FU | ||
Solid tumor | MSC-rAd.IFNβ | IFNβ | Intravenous | Preclinical | [216] | |||
Glioma | MSC-rAd.IL-12 | IL-12 | Peritumoral | Preclinical | [217] | |||
Glioma | MSC-rAd.stTRAIL | PTD, stTRAIL | Intratumoral | Preclinical | [218] | |||
Ovarian cancer | MSC-Ad5pK7-meso64-TR3 | Truncated mesothelin, TRAIL, pk7 | Intraperitoneal | Preclinical | [47] | |||
Ovarian cancer Glioma | MSC-Δ24RGD | Intravenous | Preclinical | |||||
Glioma | MSC-Ad5F35-Tet-on-E1BPro-∆24-IL-24/endostatin | IL-24/endostatin | Intravenous | Preclinical | [221] | |||
Pancreatic cancer | MSC-Ad5F3-∆E1B19K-TRAIL | ∆E1B19K, TRAIL | Preclinical | [222] | ||||
Colorectal cancer | MSC-Ad5F11-hTERT-E1AΔ24 | Intraperitoneal | Preclinical | [223] | ||||
Liver cancer | MSC-AdAFPp-E1A-miR122 | AFP promoter,microRNA-122 | Intratumoral | Preclinical | [224] | |||
Liver cancer | MSC-rAd-E1A-αCD3HAC | BiTE targeting the PD-L1 and CD3 | Intravenous | Preclinical | [225] | PBMCs | ||
Liver cancer | MSC-Ad5F35-Ha2bm-E1A-WNTi | Ha2bm promoter, WNTi | Intravenous | Preclinical | [26] | |||
Glioma | NSC-CRAd-S-pK7 | NSC-CRAd-Survivin-pK7 | pK7 | Intracranial | Phase I | NCT03072134 NCT05139056 | [30] | Tumor resection, temozolomide and radiotherapy Tumor resection |
Glioma | MSC-DNX-2401 | MSC-Ad5-∆24-RGD4C | Intraarterial | Phase I | NCT03896568 | [226] | Tumor resection | |
Glioma | MSC-ICOVIR-17 | MSC-Ad5-E2F-∆24-RGD-PH20 | PH20 | Intratumoral | Preclinical | [227] | ||
Melanoma | MSC-ICOVIR-5 | MSC-Ad5-E2F-∆24-RGD | Intravenous | Phase I | NCT01864759 | [228] | Chemotherapy and radiotherapy | |
Solid tumor | Intravenous | Phase II | NCT01844661 | |||||
Glioma | Intravenous | Phase II | NCT04758533 |